e-learning
resources
Milan 2017
Tuesday, 12.09.2017
Asthma and allergy: from the bench to the bedside
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis
S. Weinstein (Hunitngton Beach, United States of America)
Source:
International Congress 2017 – Asthma and allergy: from the bench to the bedside
Session:
Asthma and allergy: from the bench to the bedside
Session type:
Poster Discussion
Number:
3550
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Weinstein (Hunitngton Beach, United States of America). Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis. 3550
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Dupilumab improves patient-reported outcomes in uncontrolled persistent asthma patients with ongoing allergic rhinitis
Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside
Year: 2017
Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
Source: ERJ Open Res, 6 (1) 00204-2019; 10.1183/23120541.00204-2019
Year: 2020
Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline
Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges
Year: 2009
Dupilumab efficacy in children with uncontrolled, moderate-to-severe asthma with and without an allergic phenotype
Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections
Year: 2021
Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with high and low reversibility
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma
Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues
Year: 2017
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV
1
in patients with severe persistent allergic asthma irrespective of age
Source: Eur Respir J 2005; 26: Suppl. 49, 48s
Year: 2005
The impact of targeted therapy in children with uncontrolled allergic persistent severe asthma and nasal polyps
Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities
Year: 2017
Distribution of biomarkers in severe asthma and severe uncontrolled asthma
Source: Virtual Congress 2021 – Pearls in asthma and respiratory burden research
Year: 2021
IL-33 in patients with severe uncontrolled allergic asthma
Source: International Congress 2017 – "Alarming" immunological patterns in asthma
Year: 2017
Tiotropium reduces asthma exacerbations in asthmatic patients with persistent airflow obstruction uncontrolled despite treatment in accordance with guidelines
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012
Prediction of the risk of future exacerbations in patients with severe persistent allergic asthma
Source: Annual Congress 2005 - Severe asthma: perception and management
Year: 2005
The association between airway and systemic eosinophilia and symptoms and exacerbations differ between asthma and COPD patients
Source: Virtual Congress 2020 – Monitoring of inflammation in remodelling
Year: 2020
Effect of dupilumab on severe exacerbations in asthma patients with and without lung function improvements
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020
Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
The ERS/EAACI statement on severe exacerbations of asthma, and how to deal with non-allergic severe asthma
Source: International Congress 2019 – Pathophysiology and clinical insights into severe non-allergic asthma
Year: 2019
Current control, airway inflammation, and subsequent exacerbation in patients with asthma
Source: Annual Congress 2010 - Induced sputum in relation: a fresh look on phenotyping and monitoring
Year: 2010
Tiotropium improved asthma symptoms and increased time to first exacerbation in patients with moderate-to-severe asthma.
Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights
Year: 2020
Omalizumab in children with severe persistent allergic asthma
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010
Severe exacerbations predict excess lung function decline in asthma
Source: Eur Respir J 2007; 30: 452-456
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept